Empty Cities, Outstretched Hands - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Empty Cities, Outstretched Hands
What would the African healthcare crisis look like in an American landscape?


Pharmaceutical Technology


...Si lunga tratta
di gente, ch'io non avrei mai creduto
che morte tanta n'avesse disfatta.

...So long a train
of people, that I should never have believed
death had undone so many.
Dante Alighieri, The Inferno, Canto 3.


Douglas McCormick
Ninety million people live in California, Texas, New York, and Florida. Imagine that, sometime tonight, an unnameable catastrophe carries off everyone in those states over the age of 14. When the sun comes up tomorrow, only the children remain. Eighteen million children, left to care for one another or fend for themselves.

Eighteen million orphans: That's Africa today.

Last month, BD Medical (a division of Becton, Dickinson and Company, Franklin Lakes, NJ, http://www.bd.com/) hosted a two-day conference in Lyon, France, on product life-cycle management. The keynote, presented by executive vice-president Gary M. Cohen to an audience of some 200 customers and prospective customers, was not about the company's products, however.

Design for the developing world

Instead, he talked about his company's mission to provide appropriate healthcare to the world's most disadvantaged populations, taking as his text three of the eight United Nations Millennium Goals for improving the health of the world's poorest nations by 2015:

  • reduce child mortality by two-thirds;
  • reduce maternal mortality rates by three-quarters;
  • halt and begin to reverse the spread of HIV, malaria, tuberculosis, and other pandemic infectious diseases (1).

Vanished cities

Here are the dimensions of the problem: In southern Africa, HIV infects 40 million people and AIDS kills three million each year (the population of Chicago—gone). Malaria kills another three million (Philadelphia and Phoenix—gone). Tuberculosis kills two million (Houston—gone). In 2000, measles killed 850,000 (the children of San Jose, Detroit, Indianapolis, Jacksonville, and San Francisco—all gone). Maternal and neonatal tetanus, contracted by the infant or mother during childbirth on bare ground, killed 200,000 babies and 30,000 women (the children of Dallas—gone).

The litany of suffering recalled former president Bill Clinton's address at the 2006 BIO Annual Meeting in Chicago. Though we've reported it before, it bears repeating:

Keep in mind half the world's people live on less than $2.00 a day; a billion people live on less than $1.00 a day; a billion people go to bed hungry every night; a billion people never get a clean glass of water in their entire lives; . . . [each year] ten million kids die of completely preventable childhood illnesses that claim no lives in America...; and one in four of all the deaths on earth this year, all the deaths including from natural disasters, wars, accidents, crime, heart attacks, stroke, cancer, everything else in the whole world, one in four deaths will come from AIDS, TB, Malaria and infections related to dirty water, principally cholera and diarrhea-related illnesses (2).

Second-hand woes

Our industry is doing much to help, and must do more. In 2003, industry delivered more than $2 billion in aid to fight AIDS, malaria, and tuberculosis in Africa—more than the World Health Organization or UNICEF (3, 4).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here